publication date: Sep. 22, 2016
Kidney Cancer Study Finds HIF-2 Inhibitors More Effective Than Sunitinib
A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found.
HIF-2 inhibitors, which grew out of research begun more than 20 years ago at UT Southwestern Medical Center, work by interfering with processes that fuel the growth of cells.
Investigators conducted a pre-clinical trial in mice transplanted with kidney cancer from over 20 patients and showed that the HIF-2 inhibitor PT2399 controlled cancer in half of the tumors, according to a study published in the journal Nature.
“This is a completely new treatment for kidney cancer. We want to make HIF-2 inhibitors available to patients and are currently carrying out clinical trials,” said James Brugarolas, Director of the Kidney Cancer Program, who is leading an $11 million SPORE grant from the National Cancer Institute seeking to translate new discoveries into novel therapies for kidney cancer patients. Part of the SPORE grant, one of just two directly related to kidney cancer in the nation, is focused on further researching HIF-2 inhibitors.
Kevin Courtney, Assistant Professor of Internal Medicine and a coauthor of the current study, previously reported at the American Association of Clinical … Continue reading CCL 39-08 Study Finds HIF-2 Inhibitors More Effective Than Sunitinib
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.